Yari Z, Tabibi H, Najafi I, et al. - Researchers performed this randomized, double-blind, placebo-controlled trial to determine how soy isoflavone supplementation influences serum lipids and lipoprotein (a) [Lp(a)] in peritoneal dialysis (PD) patients. They randomized 40 PD patients to either the isoflavone or the placebo group. They administered 100 mg soy isoflavone daily for 8 weeks in the patients in the isoflavone group, and corresponding placebos in the placebo group. From each patient, experts collected 7 mL of blood at baseline and the end of the 8th week to measure serum triglycerides, total cholesterol, LDL-C, HDL-C, and Lp(a). According to the findings, a decrease in serum Lp(a) and a rise in HDL-C level—the two determinants of cardiovascular disease in PD patients—was brought about by daily administration of 100 mg soy isoflavones.